In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment right until illness progression or even the individuals are not able to tolerate the study drugs. - Participant consumed grapefruit or grapefruit merchandise within 3 days previous https://shanesfqcl.dailyblogzz.com/32455890/5-easy-facts-about-abbv-744-brd4-inhibitor-mechanism-of-action-described